Status:
COMPLETED
Selenium in the Prevention of Cancer
Lead Sponsor:
Odense University Hospital
Collaborating Sponsors:
Danish Cancer Society
University of Southern Denmark
Conditions:
Cancer
Eligibility:
All Genders
60-74 years
Phase:
NA
Brief Summary
This is a pilot study proceeding an intended international trial. Hypothesis: Daily intake of selenium supplementation in the form of selenium-enriched yeast tablets will reduce the risk of cancer in...
Eligibility Criteria
Inclusion
- Inclusion Criteria:
- WHO performance status 0 or 1
- No active liver- or kidney disease (Serum ALAT (alanine aminotransferase), alkalic phosphatase, bilirubin, creatinin or urea within 2 S.D of laboratory reference range)
- No previous cancer diagnosis
- No known HIV-infection
- Participant must understand oral and written information
- Participant must not use selenium supplementation of above 50 mcg/d
- Participant must give written consent prior to inclusion
Exclusion
Key Trial Info
Start Date :
November 1 1998
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 1 2004
Estimated Enrollment :
491 Patients enrolled
Trial Details
Trial ID
NCT01819649
Start Date
November 1 1998
End Date
June 1 2004
Last Update
September 14 2017
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Selenium Centre, Odense University Hospital
Odense C, Denmark, 5000